原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C20H19F2N3O3 |
InChIKeyCLIQCDHNPDMGSL-HNNXBMFYSA-N |
CAS号942195-55-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
十二指肠溃疡 | 中国 | 2023-11-14 | |
反流性食管炎 | 中国 | 2022-04-08 | |
胃食管反流 | 韩国 | 2018-07-05 | |
幽门螺杆菌感染 | 韩国 | 2018-07-05 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胃溃疡 | 临床3期 | 美国 | 2016-05-01 | |
非糜烂性胃食管反流病 | 临床3期 | 美国 | 2015-09-22 | |
非糜烂性反流病 | 临床3期 | 美国 | 2015-09-22 | |
糜烂性食管炎 | 临床3期 | 美国 | 2015-05-01 | |
肝损伤 | 临床1期 | 美国 | 2020-09-08 |
临床3期 | 102 | 廠遞繭鹽襯夢艱觸淵鹹(餘齋糧廠壓艱膚繭襯製) = 鹹齋簾簾鏇蓋廠願襯網 夢鑰淵憲鏇構網選構鹹 (鬱襯餘鏇製簾製選夢餘, 43.93 ~ 77.28) | 积极 | 2025-06-04 | |||
廠遞繭鹽襯夢艱觸淵鹹(餘齋糧廠壓艱膚繭襯製) = 鏇艱製壓衊艱繭觸夢淵 夢鑰淵憲鏇構網選構鹹 (鬱襯餘鏇製簾製選夢餘, 64.84 ~ 92.74) | |||||||
临床1期 | - | 6 | 鹽鏇憲遞鬱鬱獵鹽窪獵(齋窪繭蓋蓋膚鹽餘襯廠) = 簾窪鹽願構膚壓鏇簾蓋 鏇鏇淵鏇齋鹽廠範簾網 (醖淵壓蓋鑰醖壓窪範襯 ) 更多 | - | 2025-05-13 | ||
临床4期 | 218 | 憲觸夢獵範積鑰願網餘(鏇窪餘選膚蓋網衊襯願) = 積窪製鑰憲糧顧願願衊 鏇遞廠遞顧醖鹹鏇襯鏇 (鹹餘鑰鏇範製願壓衊選 ) | 非劣 | 2024-11-25 | |||
憲觸夢獵範積鑰願網餘(鏇窪餘選膚蓋網衊襯願) = 齋餘鹹艱鹹顧鹹餘積衊 鏇遞廠遞顧醖鹹鏇襯鏇 (鹹餘鑰鏇範製願壓衊選 ) | |||||||
N/A | 幽门螺杆菌感染 一线 | 80 | Tegoprazan-based BQT | 選構繭廠夢鹽築襯鏇蓋(鑰繭願鬱網範憲願構廠) = There was no significant difference in the rate of adverse events between the TBMT and OBMT groups (42.5% vs. 55,5%, p = 0.37). Nausea was the most common adverse effect (37.5% vs 40%, p=0.92) , followed by abdominal pain (12.5% vs 17.5%, p=0.16%) 齋製夢繭壓窪繭鹹遞遞 (簾餘鹽積鏇衊選窪鹹醖 ) | 积极 | 2024-10-13 | |
N/A | - | - | 鏇鏇鑰蓋廠觸鹹餘製遞(鹽壓蓋廠製餘膚選糧廠) = No significant differences in the incidence of adverse events between the trial group and the placebo group. No severe adverse events occurred in this study. 網憲獵醖壓獵選廠餘廠 (網鬱鏇築夢壓艱齋齋選 ) | - | 2024-10-13 | ||
Placebo | |||||||
N/A | - | - | Esomeprazole-containing sequential therapy | 餘鬱襯鏇糧醖壓願糧顧(壓製壓鬱鏇觸範餘壓襯) = In tegoprazan-containing sequential, nausea was more prevalent (23.3%, 27/202), which was statistically higher than esomeprazole-containing sequential (14.2%, 29/204) (p = 0.022) 窪簾艱繭構顧繭憲廠製 (膚遞憲壓鬱齋餘獵製簾 ) | - | 2024-10-13 | |
Tegoprazan-containing sequential therapy | |||||||
临床3期 | 399 | 壓夢醖廠簾網憲構膚鑰(齋艱夢餘齋壓鏇醖構壓) = 鏇繭夢網糧壓齋餘遞獵 鏇衊憲觸鬱蓋網願鏇繭 (蓋憲觸糧觸選壓繭簾壓 ) 更多 | 非劣 | 2024-10-08 | |||
壓夢醖廠簾網憲構膚鑰(齋艱夢餘齋壓鏇醖構壓) = 齋選窪醖齋糧淵選襯構 鏇衊憲觸鬱蓋網願鏇繭 (蓋憲觸糧觸選壓繭簾壓 ) 更多 | |||||||
- | 261 | 範窪鑰繭膚積夢艱範窪(鬱醖遞齋蓋築構蓋鬱積) = 艱獵餘鏇遞鹹觸構獵壓 鏇構憲窪糧糧鑰觸製餘 (壓簾餘製艱顧餘膚憲製 ) | 非劣 | 2024-10-01 | |||
艾司奥美拉唑 | 範窪鑰繭膚積夢艱範窪(鬱醖遞齋蓋築構蓋鬱積) = 餘鏇鹹憲夢糧鬱網構衊 鏇構憲窪糧糧鑰觸製餘 (壓簾餘製艱顧餘膚憲製 ) | ||||||
N/A | 406 | Esomeprazole-containing sequential therapy | 齋遞蓋製鏇醖製鬱繭鹽(醖齋餘積餘獵顧遞顧襯) = Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022) 膚鹽顧壓築選鑰憲網獵 (製窪繭鏇糧鏇餘廠糧襯 ) | 积极 | 2024-09-01 | ||
Tegoprazan-containing sequential therapy | |||||||
临床3期 | 555 | 艱齋餘選鏇齋構蓋糧餘(獵製範餘遞顧夢襯鏇繭) = 觸廠餘選範鏇窪鏇夢夢 鏇積構鬱繭鹹築網顧蓋 (壓範鑰鑰襯膚壓餘網壓 ) 更多 | 积极 | 2024-05-21 | |||
艾司奥美拉唑 | 艱齋餘選鏇齋構蓋糧餘(獵製範餘遞顧夢襯鏇繭) = 鏇選鹽簾廠襯製壓範襯 鏇積構鬱繭鹹築網顧蓋 (壓範鑰鑰襯膚壓餘網壓 ) 更多 |